Therapy Directory

Pembrolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention. Browse Pembrolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:08 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1847

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Glioma
Interventions: Pembrolizumab, Olaparib and Temozolomide; Drug · Combination Product
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more

Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions: tisotumab vedotin, pembrolizumab, carboplatin, cisplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 124
States / cities: Encinitas, California • La Jolla, California • Sacramento, California + 57 more

Conditions: Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
Interventions: iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab; Genetic · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more

Conditions: Urothelial Carcinoma
Interventions: disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 89
States / cities: Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more

Conditions: Ovarian Cancer
Interventions: Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Non Small Cell Lung Cancer
Interventions: Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy; Diagnostic Test · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma
Interventions: PF-08046054, pembrolizumab; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Irvine, California • Orange, California + 12 more

Conditions: Brain Metastases
Interventions: Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery; Drug · Radiation · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer
Interventions: Pembrolizumab, ALX148, Doxorubicin; Drug
Lead sponsor: Alexander B Olawaiye, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Fullerton, California • Peoria, Illinois • The Bronx, New York + 1 more

Conditions: Lung Cancer, Non-Small Cell
Interventions: Dostarlimab, Belrestotug, Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more

Conditions: Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
Interventions: Palbociclib, Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

About this Pembrolizumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pembrolizumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Pembrolizumab clinical trials

Filter and sort this therapy

Live official records

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Pembrolizumab In Central Nervous System Metastases

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Palbociclib and Pembrolizumab In Central Nervous System Metastases

About this Pembrolizumab clinical trials directory page